Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

被引：11
|
作者：
Hamilton, E. P. [1 ]
Barve, M. A. [2 ]
Tolcher, A. W. [3 ]
Buscema, J. [4 ]
Papadopoulos, K. P. [5 ]
Zarwan, C. [6 ]
Anderson, C. K. [7 ]
Doroshow, D. [8 ]
Wang, D. [9 ]
Huebner, D. [10 ]
Jansen, V. M. [10 ]
Jarlenski, D. [10 ]
Mosher, R. [10 ]
Kaufman, J. [10 ]
Moore, K. N. [11 ]
Richardson, D. L. [11 ]
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
[2] Mary Crowley Canc Res, Med Oncol, Dallas, TX USA
[3] NEXT OncologyTM, San Antonio, TX USA
[4] Arizona Oncol Associates, Oncol, Tucson, AZ USA
[5] South Texas Accelerated Res Therapeut START, Clin Res, San Antonio, TX USA
[6] Lahey Hosp & Med Ctr, Oncol, Burlington, MA USA
[7] Willamette Valley Canc Inst, Oncol, Eugene, OR USA
[8] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Hematol Oncol, New York, NY 10029 USA
[9] Henry Ford Hosp, Hematol Oncol, Detroit, MI 48202 USA
[10] Mersana Therapeut Inc, Clin Dev, Cambridge, MA USA
[11] Univ Oklahoma, Sarah Cannon Res Inst, Stephenson Canc Ctr, Gynecol Oncol Dept, Oklahoma City, OK USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.975
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
836P
引用
收藏
页码：S627 / S628
页数：2
相关论文
共 50 条
  • [11] COMPARISON OF NAPI2B EXPRESSION FROM PAIRED TISSUE SAMPLES IN A CLINICAL STUDY OF UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) SUPPORTS A STRATEGY OF TESTING IN ARCHIVE MATERIAL
    Richardson, Debra
    Barve, Minal
    Saltos, Andreas
    Papadopoulos, Kyriakos
    Hays, John
    Tolcher, Anthony
    Ellard, Susan
    Doroshow, Deborah
    Mitchell, Paul
    Zarwan, Corrine
    Werner, Theresa
    Anderson, Charles
    Spira, Alex
    Mileshkin, Linda
    Bradshaw, Chelsea
    Demars, Leslie
    Mosher, Rebecca
    Hamilton, Erika
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A55 - A56
  • [12] Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.
    Richardson, Debra L.
    Hamilton, Erika P.
    Oaknin, Ana
    Randall, Leslie M.
    Banerjee, Susana N.
    Taylor, Sara Kristina
    Mileshkin, Linda R.
    Coleman, Robert L.
    Monk, Bradley J.
    Mirza, Mansoor Raza
    Bernardo, Patricia
    Mosher, Rebecca
    Jansen, Valerie Malyvanh
    Savarese, Antonella
    Van Gorp, Toon
    Madry, Radoslaw
    Ray-Coquard, Isabelle Laure
    Concin, Nicole
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [13] UPLIFT (ENGOT-OV67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer
    Richardson, Debra
    Concin, Nicole
    Hays, John
    Perez Fidalgo, Jose Alejandro
    Pothuri, Bhavana
    Banerjee, Susana
    Ghamande, Sharad
    Ray Coquard, Isabelle
    Germanova, Anna
    Rimel, Bobbie
    Lorusso, Domenica
    Cloven, Noelle
    Baurain, Jean-Francois
    Randall, Leslie
    Brasiuniene, Birute
    Tseng, Jill
    Klasa-Mazurkiewicz, Dagmara
    Werner, Theresa
    Oaknin, Ana
    Ang, Joo Ern
    Leary, Alexandra
    Bishop, Erin
    Marth, Christian
    Bradshaw, Chelsea
    Burger, Robert
    Gonzalez Martin, Antonio Jose
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S56 - S56
  • [14] Results from the phase 1 dose escalation study of XMT-1592, a dolasynthen NAPI2B-directed antibody-drug conjugate (ADC)
    Hamilton, Erika P.
    Papadopoulos, Kyriakos P.
    Barve, Minal
    Lakhani, Nehal
    Burns, Timothy F.
    Burger, Robert A.
    Reske, Adi
    Wekheye, Kelley
    Tolcher, Anthony
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A343 - A343
  • [15] XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma
    Fessler, Shawn
    Dirksen, Anouk
    Collins, Scott D.
    Xu, Ling
    Lee, Winnie
    Wang, Jason
    Eydelloth, Ron
    Ter-Ovanesyen, Elena
    Zurita, Jeffrey
    Ditty, Elizabeth
    Nehilla, Barrett
    Clardy, Susan
    Carter, Tyler
    Avocetien, Kenneth
    Nazzaro, Mark
    Le, Nam
    Catcott, Kalli C.
    Uttard, Alex
    Du, Bingfan
    Chin, Chen-Ni
    Mosher, Rebecca
    Slocum, Kelly
    Qin, Liuliang
    Lee, David
    Toader, Dorin
    Damelin, Marc
    Lowinger, Timothy B.
    CANCER RESEARCH, 2020, 80 (16)
  • [16] XMT-1660: A phase I, first-in-human trial of a B7-H4-directed dolasynthen antibody-drug conjugate in ovarian, endometrial, and breast cancers
    Burger, Robert
    Hamilton, Erika
    Adams, Sylvia
    Han, Hyo
    Spira, Alexander
    Giordano, Antonio
    Chaudhry, Arvind
    Parajuli, Ritesh
    Wang, Judy
    Weise, Amy
    Abuhadra, Nour
    McNamara, Patrick
    Kalinsky, Kevin
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S282 - S282
  • [17] A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC)
    Burris, Howard A.
    Gordon, Michael S.
    Gerber, David E.
    Spigel, David R.
    Mendelson, David S.
    Schiller, Joan H.
    Wang, Yulei
    Choi, Younleong
    Kahn, Robert S.
    Wood, Katie
    Maslyar, Daniel J.
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [18] Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
    Trudel, Suzanne
    Lendvai, Nikoletta
    Popat, Rakesh
    Voorhees, Peter M.
    Reeves, Brandi
    Libby, Edward N.
    Richardson, Paul G.
    Hoos, Axel
    Gupta, Ira
    Bragulat, Veronique
    He, Zangdong
    Opalinska, Joanna B.
    Cohen, Adam D.
    BLOOD CANCER JOURNAL, 2019, 9 (4)
  • [19] SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE ANTI-NAPI2B ANTIBODY-DRUG CONJUGATE DNIB0600A: A PHASE I STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND PLATINUM-RESISTANT OVARIAN CANCER
    Gerber, David
    Infante, Jeffrey
    Gordon, Michael
    Schiller, Joan
    Spigel, David
    Wang, Yulei
    Shames, David S.
    Choi, Younjeong
    Kahn, Robb
    Xu, Jian
    Lin, Kedan
    Wood, Katie
    Maslyar, Daniel
    Burris, Howard
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1190 - S1191
  • [20] Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
    Moore, Kathleen N.
    Birrer, Michael J.
    Marsters, Jim
    Wang, Yulei
    Choi, YounJeong
    Royer-Joo, Stephanie
    Lemahieu, Vanessa
    Armstrong, Katy
    Cordova, Julie
    Samineni, Divya
    Schuth, Eva
    Vaze, Anjali
    Maslyar, Daniel
    Humke, Eric W.
    Hamilton, Erika P.
    Liu, Joyce F.
    GYNECOLOGIC ONCOLOGY, 2020, 158 (03) : 631 - 639
12345